Ultragenyx Pharmaceutical shares are trading higher after Cantor Fitzgerald reiterated its Overweight rating on the stock and maintained a $107 price target.
Portfolio Pulse from Benzinga Newsdesk
Ultragenyx Pharmaceutical's stock (RARE) is trading higher following Cantor Fitzgerald's reiteration of its Overweight rating and a maintained price target of $107.
April 05, 2024 | 7:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald reaffirmed its Overweight rating on Ultragenyx Pharmaceutical and maintained a $107 price target, leading to a positive movement in the stock.
Analyst ratings, especially from reputable firms like Cantor Fitzgerald, can significantly influence investor sentiment and stock prices. The reiteration of an Overweight rating and a high price target suggests strong confidence in the company's future performance, likely leading to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100